Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

hase 2 clinical trial in patients with non-Hodgkin's lymphoma with blinatumomab. In addition, by mid-2009, we expect to have completed enrollment in the ongoing phase 2 clinical trial in patients with acute lymphoblastic leukemia.
  • By mid 2009, we expect our partner Nycomed to initiate the first phase 1 clinical trial with MT203, a GM-CSF-neutralizing human monoclonal antibody, for the treatment of chronic inflammatory and autoimmune diseases.
  • Later in 2009, we expect our partner Morphotek, a wholly-owned subsidiary of Eisai, to initiate a first phase 1 clinical trial with MT228, a glycolipid-binding human antibody.
  • Also later in 2009, we expect our partner TRACON Pharmaceuticals, Inc. to complete the ongoing phase 1 clinical trial of MT293, a humanized monoclonal antibody targeting denatured collagen, that is being developed for the treatment of solid tumors.
  • Micromet intends to publish results from the research and development of its programs in peer-reviewed scientific and clinical journals throughout the year.
  • As previously stated, Micromet entered into an agreement with Bayer Schering in January 2009 under which Bayer Schering has obtained an exclusive option to develop and commercialize a BiTE antibody against a specified solid tumor target. We intend to enter into at least one additional corporate collaboration in 2009.
  • Financial Results:

    Quarter Ended December 31, 2008

    For the three months ended December 31, 2008, Micromet recognized total revenues of $5.9 million, compared to $7.0 million for the same period in 2007. Total operating expenses were $12.4 million for the three months ended December 31, 2008, compared to $13.1 million for the same period in 2007.

    Loss from operations for the three months ended December 31, 2008 was $6.5 million, compared to a loss from operations of
    '/>"/>

    SOURCE Micromet, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
    2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
    3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
    4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
    5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
    6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
    7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
    8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
    9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
    10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
    11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... led by group leader Yung-Eun Sung has announced ... sulfur-doped and nitrogen-doped graphenes which can be applied ... fuel cells. Yung-Eun Sung is both a group ... Institute for Basic Science* (IBS) and a professor ... has great significance with regards to the development ...
    (Date:7/24/2014)... , July 24, 2014 Research and ... "Global Genomics and Proteomics Analytical Instruments Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the study of ... study of the structure and functions of proteomes or ... tools and technology. Genomics involves the mapping of genes ...
    (Date:7/24/2014)... (PRWEB) July 24, 2014 2014 ... Sulphate Industryā€¯ is a professional and in-depth research ... introduces Potassium Sulphate basic information, including its ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
    (Date:7/24/2014)... July 24, 2014 Draper University, ... is proud to announce that for 6 weeks ... countries will converge on the Draper University campus ... intensive, experiential program focused on entrepreneurship, building real-world ... school, currently running its sixth cohort, continues to ...
    Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3
    ... Laureate To Manufacture Tolera,s Monoclonal Antibody Product ... Laureate Pharma, Inc., a,full-service biopharmaceutical development ... has entered into a cGMP contract manufacturing,agreement ... that,develops and offers targeted therapies and safer ...
    ... will feature Ziplex automated gene-expression system at the ... ... Xceed Molecular, a pioneer in,the development of cost-effective, easy-to-use ... Dr. James L. Wittliff, a professor in the Department of,Biochemistry ...
    ... ... Gardner, Mass. (PRWEB) October 28, 2008 -- New England Peptide, ... formed scientific advisory board., , ,Vincent Bille, Tomi Sawyer and Ved ... thought leaders in peptide chemistry. The group will assist in formulating ...
    Cached Biology Technology:Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc. 2James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30 2James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30 3New England Peptide Forms Scientific Advisory Board 2New England Peptide Forms Scientific Advisory Board 3New England Peptide Forms Scientific Advisory Board 4
    (Date:7/25/2014)... tractography (DTT), which is derived from diffusion tensor ... motor tracts, such as the corticospinal tract, the ... The corticospinal tract is known to be a ... human brain. Several studies have reported on injury ... addition, some studies have demonstrated recovery of a ...
    (Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
    (Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
    Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2
    ... discovered that a poorly understood class of RNA produced in ... the outcome of the infection. Their findings are reported ... Society for Microbiology. RNA (ribonucleic acid) contains information transcribed ... known of these RNAs translate sections of DNA code into ...
    ... St. Louis, MO, October 26, 2010 Periodontitis, a ... teeth, leads to accumulation of bacteria and potential bone ... bacterial infection, more recent strategies target the inflammatory response. ... Journal of the American Dietetic Association , researchers ...
    ... Food and Agriculture (NIFA) awarded a $1.5 million grant ... for increasing environmental, social, and economic sustainability in ornamental ... the U of I Department of Crop Sciences said ... crop production systems is waste generation due to the ...
    Cached Biology News:New class of biomolecules triggered in response to respiratory virus infection 2New class of biomolecules triggered in response to respiratory virus infection 3New class of biomolecules triggered in response to respiratory virus infection 4Consuming polyunsaturated fatty acids may lower the incidence of gum disease 2U of I receives $1.5 million to further sustainability in ornamental crop production 2U of I receives $1.5 million to further sustainability in ornamental crop production 3
    ... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
    ... and conveniently controls the temperature at your lab ... levels up to 99 C*, with the "plus" ... as 5 C. The thermoblocks for 0.2 ml**, ... microplates enable a high degree of flexibility for ...
    ...
    ... powerful tool for sample purification in microbiological ... or protein purification as well as cell ... on the Genesis Series of instruments using ... with the RoMa arm and Tecans powerful ...
    Biology Products: